Skip to content

Medical emergency? What to do

Drugs plug gap as world awaits bird flu vaccine

3-RXPublished September 14, 20054 min read

Key points

  • Scientists believe they have the know-how to make an effective vaccine against pandemic bird flu; the problem is how to make enough of it.
  • But current global manufacturing capacity, at around 300 million regular flu doses a year, is simply insufficient to meet global needs during a pandemic.
  • Adding new production will take time, raising fears that many poor parts of the world are likely to go without.
  • There will also be a hiatus of four to six months while factories switch to making a pandemic version, once a new strain of humanized bird flu is identified.

Scientists believe they have the know-how to make an effective vaccine against pandemic bird flu; the problem is how to make enough of it.

As avian flu spreads from Asia into Siberia and Kazakhstan, health experts are increasingly focused on the medical challenge of fighting the disease should it "go human" and start to spread easily from person to person.

A vaccine is the best hope to prevent millions of deaths.

But current global manufacturing capacity, at around 300 million regular flu doses a year, is simply insufficient to meet global needs during a pandemic.

"If you need to vaccinate the whole world, you are not going to do that with existing capacity, which is basically aimed at the over-65s in the West," said Tony Colegate of Chiron Corp, who coordinates production issues for the Influenza Vaccine Supply Task Force, an international industry group.

Adding new production will take time, raising fears that many poor parts of the world are likely to go without.

At present, 90 percent of capacity is concentrated in Europe and North America, and the World Health Organization (WHO) says past experience suggests governments will be reluctant to release supplies for export before domestic demand is fully met.

There will also be a hiatus of four to six months while factories switch to making a pandemic version, once a new strain of humanized bird flu is identified.

BUYING TIME

In the absence of a vaccine, the job of holding pandemic flu at bay will rest largely on a limited stockpile of antiviral drugs, called neuraminidase inhibitors, that can reduce the severity of flu infection and can speed patients' recovery.

This could buy valuable time to produce a vaccine and introduce other emergency measures, according to the WHO, which accepted a donation of 3 million doses of Swiss drug firm Roche's Tamiflu medicine in August.

Britain's GlaxoSmithKline says it may make a similar, but smaller, donation of its drug Relenza.

The hope is that intensive use of neuraminidase inhibitors in an area where a pandemic is emerging will delay its spread, or even nip it in the bud altogether.

In the meantime, scientists will be working overtime on vaccine development.

The good news is that some of the technical issues surrounding bird flu vaccine are being resolved.

Although a specific vaccine against pandemic virus cannot be made until the final strain emerges, most experts think the H5N1 strain now circulating is the one they need to target.

As with seasonal flu, the vaccine can be adjusted as the virus changes but the hope is that it will not mutate so much as to escape protection offered by the vaccines now in development.

The most advanced H5N1 vaccine, from France's Sanofi-Aventis SA, has already proved effective at stimulating an immune system response in healthy adults and others are in the pipeline.

U.S.-based Chiron aims to test its H5N1 vaccine in the fall and GlaxoSmithKline plans large-scale clinical trials in 2006.

Even so, Nomura pharmaceuticals analyst Michael Leacock estimates only 75 million doses can be made within a year -- equal to just one-quarter of current seasonal flu vaccine output.

And that would require abandoning production of vaccine for seasonal flu, which regularly kills 250,000 to 500,000 people a year.

The H5N1 strain has so far killed more than 60 people in Asia since 2003, but experts fear it will mutate into a mass killer of millions if it becomes more infectious.

CHICKEN AND EGG

Much of the problem lies in the tricky nature of flu vaccine production, which involves cultivation in embryonated chicken eggs and yields only limited amounts of antigen -- the key component of a vaccine that triggers an immune response.

Stretching antigen supplies is therefore crucial.

The problem is particularly acute because the quantity of antigen needed to get a response to a bird flu vaccine is much greater than normal.

One way round this may be to use adjuvants -- compounds added to a vaccine to boost the immune response -- or else to inject vaccine under the skin rather than into muscle.

The long-term answer is to adopt better technology and move away from chicken egg production, which could in any case be at risk if bird flu leads to mass slaughter of poultry.

Cultivating antigen in stainless steel vats of cell culture is widely seen as the way of the future.

But David Fedson, a leading expert on flu vaccines and a former senior executive at Sanofi-Aventis, says cell culture will have little effect on capacity within the next five years.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underFlu

Keep reading

Flu

Masks, hand sanitizer help halt flu spread

Want to be prepared for a flu pandemic? You may want to stock up on face masks and hand sanitizer, according to a new study. College students living in residency halls who wore the masks for a few hours a day and…

3 min read

Flu

Uzbekistan says closed Kazakh border due to flu

Uzbekistan said on Wednesday it had closed the border with Central Asian neighbour Kazakhstan as part of a seasonal anti-flu quarantine. On Monday, Kazakhstan said Uzbekistan shut the border without any explanations…

1 min read

Flu

Worst case H1N1 may cut UK economy by 4.3 percent

- A severe H1N1 flu pandemic could cost the UK economy 72 billion pounds ($121 billion), British scientists said on Friday, but advised against closing schools even if the current mild pandemic takes a turn for the…

3 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.